Sunshine Biopharma (NASDAQ:SBFM) Stock Price Down 2% – Here’s What Happened

Sunshine Biopharma, Inc. (NASDAQ:SBFM)’s share price fell 2% on Tuesday . The company traded as low as $1.00 and last traded at $1.00. 31,005 shares were traded during trading, a decline of 16% from the average session volume of 36,894 shares. The stock had previously closed at $1.02.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sunshine Biopharma in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.00.

Sunshine Biopharma Stock Performance

The stock has a market capitalization of $4.91 million, a P/E ratio of -0.98 and a beta of 1.51. The business has a fifty day simple moving average of $1.17 and a 200-day simple moving average of $1.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Sunshine Biopharma in the fourth quarter worth $29,000. Two Sigma Investments LP bought a new stake in Sunshine Biopharma in the third quarter valued at $32,000. Finally, Citadel Advisors LLC raised its holdings in shares of Sunshine Biopharma by 23.1% during the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock valued at $116,000 after purchasing an additional 14,656 shares during the period. 41.98% of the stock is owned by institutional investors.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.